Multinational Etoricoxib and Diclofenac Arthritis Long-Term Study Program - MEDAL Program – Presented at AHA 2006


The goal of the MEDAL study program was to evaluate the risk of thrombotic cardiovascular events with etoricoxib, a highly selective cyclooxygenase-2 (COX-2) inhibitor, compared with the nonsteroidal anti-inflammatory drug (NSAID) diclofenac among patients with osteoarthritis and rheumatoid arthritis.